On January 28th and 29th, Venn Life Sciences and its partner CEA (Pr. Daniel Gillet’s team) hosted a workshop gathering European experts on Hemolytic Uremic Syndrome caused by Shiga Toxin-producing… read more →
Venn Life Sciences Holdings Plc (“Venn” or the “Company”) Partnership Announcement Venn Life Sciences (“Venn”) an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial… read more →
Venn Life Sciences Holdings Plc (“Venn” or the “Company”) Strategic Collaboration Agreement with Open Orphan DAC and Financing Venn Life Sciences (“Venn”) an Integrated Drug Development Partner offering a combination… read more →
Venn Life Sciences Holdings Plc (“Venn” or the “Company”) Trading Update and Change of Adviser November 8, 2018 Venn Life Sciences (“Venn”) an Integrated Drug Development Partner offering a combination… read more →
Why partner with Venn’s Pharmacokinetics Team? Venn Life Sciences contributes to International Partnership for Microbicides (IPM) clinical pharmacology program by providing a diverse range of services (e.g. consultancy, non-compartmental pharmacokinetic… read more →